United States · Bill · S
S. 4340 (117th)
EFFECTIVE Act
Introduced
26 May 2022
Last action
26 May 2022 · Introduced
Status
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsors
Sen. Manchin, Joe, III [I-WV], Sen. Braun, Mike [R-IN]
Subjects
Healthcare
Source updated
5 December 2025
Summary
Ensuring the FDA Fully Examines Clinical Trial Impact and Vitalness before Endorsement Act or the EFFECTIVE Act This bill specifies that the Food and Drug Administration may deny an application for a new opioid analgesic drug upon a determination that the drug does not provide a significant advantage or clinical superiority compared to other drugs.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
26 May 2022
Introduced
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Source: IntroReferral
26 May 2022
Introduced
Introduced in Senate
Source: IntroReferral
Votes
No vote records are attached yet.
Versions
- Introduced in Senate · 26 May 2022 · Official file
Documents
3 official files
Introduced in Senate (text)
Introduced in Senate · EN · 26 May 2022
Introduced in Senate (PDF)
Introduced in Senate · EN · 26 May 2022
Introduced in Senate
summary · EN · 26 May 2022
Sponsors
- Sen. Manchin, Joe, III [I-WV] · D · Sponsor
- Sen. Braun, Mike [R-IN] · R · Sponsor
- · sshr00 · Standing
Related records
- related to → EFFECTIVE Act
- related to ← EFFECTIVE Act
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/117th-congress/senate-bill/4340
- Open data entity: https://api.congress.gov/v3/bill/117/s/4340
- us · 117-s-4340 · source updated 5 December 2025